How to Get Jatenzo in Wisconsin

Wisconsin Law Allows Telehealth Prescribing of Jatenzo

Wisconsin permits licensed prescribers to write Schedule III controlled substance prescriptions via telehealth, which means Jatenzo is accessible without an in-person office visit. Under Wisconsin Statute § 448.015 and the state Medical Examining Board's telehealth rules, a provider must establish a valid patient-provider relationship through a synchronous audio-video encounter before prescribing. This relationship cannot be formed through questionnaire-only platforms.

The prescriber must hold an active Wisconsin medical license or be authorized through the Interstate Medical Licensure Compact (IMLC), which Wisconsin joined in 2017. Nurse practitioners in Wisconsin can prescribe Schedule III substances under a collaborative agreement with a physician, per Wisconsin Administrative Code Chapter N 8. Physician assistants may also prescribe under their supervising physician's DEA registration.

One practical note: the Ryan Haight Act requires that the prescribing clinician either sees you in person at least once or holds a valid DEA registration with a specific telehealth modifier. Most reputable telehealth TRT platforms satisfy this through an initial video consultation followed by periodic check-ins every 90 to 180 days.

Labs Required Before a Wisconsin Jatenzo Prescription

Two separate morning serum total testosterone measurements confirming levels below 300 ng/dL are the clinical prerequisite. The Endocrine Society's 2018 guidelines specify that blood draws should occur between 7:00 AM and 10:00 AM, when testosterone levels peak, and that the diagnosis of hypogonadism requires at least two confirmatory results on different days.

Beyond total testosterone, most prescribers in Wisconsin will order a baseline panel that includes:

• Free testosterone (calculated or measured via equilibrium dialysis)
• Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to distinguish primary from secondary hypogonadism
• Complete blood count, specifically hematocrit, since testosterone therapy raises red blood cell mass
• Comprehensive metabolic panel including liver enzymes (AST, ALT)
• Lipid panel
• Prostate-specific antigen (PSA) for men over 40

Jatenzo carries a specific FDA boxed warning for blood pressure elevation. In the key registration trial by Swerdloff et al. (2020, N=166), systolic blood pressure increased by a mean of 3.3 mmHg at day 120, and 5.8% of subjects experienced a systolic reading above 140 mmHg during the study period. Prescribers should therefore obtain baseline blood pressure readings and document them in the chart before initiating therapy.

The FDA-approved prescribing information for Jatenzo also recommends monitoring hematocrit at 3 months, 6 months, and annually thereafter, with a threshold of 54% triggering dose reduction or discontinuation.

How Jatenzo Dosing Works

Jatenzo is an oral testosterone undecanoate capsule taken twice daily with food. That last part matters. The drug uses a self-emulsifying delivery system that relies on dietary fat for lymphatic absorption, bypassing first-pass hepatic metabolism. Taking it on an empty stomach reduces bioavailability by roughly 40%, according to pharmacokinetic data in the Swerdloff et al. trial.

Starting dose is 237 mg twice daily. After approximately 14 days, the prescriber checks a serum total testosterone level drawn 4 to 6 hours post-dose. Based on that result, the dose is titrated:

• If testosterone is below 350 ng/dL, increase to 396 mg twice daily
• If testosterone is between 350 and 1 to 050 ng/dL, maintain at 237 mg twice daily
• If testosterone exceeds 1 to 050 ng/dL, reduce to 158 mg twice daily
• If testosterone remains above 1 to 050 ng/dL at the 158 mg dose, discontinue

This titration protocol differs from injectable testosterone, where levels fluctuate significantly between peak and trough. Oral testosterone undecanoate produces a more stable pharmacokinetic profile, which may reduce mood swings and energy dips that some patients report with injectable formulations.

Wisconsin Medicaid Coverage and Prior Authorization

Wisconsin Medicaid (BadgerCare Plus and fee-for-service) covers Jatenzo for the FDA-approved indication of male hypogonadism, but prior authorization is required. The PA process typically asks for documentation of:

1. Two morning serum testosterone values below 300 ng/dL, drawn on separate days
2. Clinical signs and symptoms of hypogonadism (fatigue, decreased libido, loss of muscle mass, depressed mood)
3. Exclusion of reversible causes (obesity-related suppression, opioid use, pituitary pathology)
4. Documented trial of or contraindication to injectable testosterone cypionate or enanthate, which most formularies consider first-line due to lower cost

That fourth point is where many PA requests fail on initial submission. Wisconsin Medicaid's preferred drug list generally treats injectable testosterone as step therapy before oral formulations. Documenting a specific clinical reason for preferring the oral route (needle phobia, history of injection-site reactions, polycythemia on injectables, or inability to self-inject) strengthens the PA request.

For patients with commercial insurance, coverage varies widely. The Jatenzo manufacturer website lists a savings card program that may reduce copays for commercially insured patients, though eligibility excludes government insurance beneficiaries. Average wholesale price for Jatenzo sits around $850 per month without insurance, making the PA process worth pursuing.

503A Compounding Pharmacies in Wisconsin

Wisconsin licenses 503A compounding pharmacies under the state Pharmacy Examining Board (Wisconsin Administrative Code Chapter Phar 7). These pharmacies can compound oral testosterone undecanoate capsules from bulk powder when a valid patient-specific prescription exists. This is not Jatenzo (a brand-name product with a specific formulation), but it is the same active pharmaceutical ingredient.

A few distinctions matter here. 503A compounded testosterone undecanoate has not undergone the same bioequivalence testing that Jatenzo completed for FDA approval. The self-emulsifying drug delivery system in brand Jatenzo is proprietary, and compounded versions may use different excipients that affect absorption. The Endocrine Society has cautioned that compounded hormones lack the standardized potency testing of FDA-approved products, though they acknowledge a role when commercial products are unavailable or unaffordable.

Compounded oral testosterone undecanoate capsules from a Wisconsin 503A pharmacy typically cost $120 to $250 per month, a significant reduction from brand Jatenzo's cash price. The trade-off is variable bioavailability and the absence of an FDA-mandated REMS monitoring program.

Wisconsin 503A pharmacies can ship within the state, and some hold non-resident pharmacy licenses in neighboring states (Minnesota, Iowa, Illinois, Michigan), allowing cross-border shipment where permitted.

Finding a Prescriber in Wisconsin

Multiple pathways exist for Wisconsin residents seeking a Jatenzo prescription. The choice depends on geography, insurance status, and personal preference.

Endocrinologists and urologists. The most traditional route. Wisconsin has approximately 180 board-certified endocrinologists, with the highest concentration in Milwaukee, Madison, and Green Bay metro areas. Wait times for a new-patient endocrinology appointment average 4 to 8 weeks statewide. Urologists who specialize in men's health or andrology also prescribe testosterone therapy and may have shorter wait times.

Primary care providers. Family medicine physicians and internists in Wisconsin can prescribe Jatenzo. The American Urological Association's 2018 guidelines on testosterone deficiency support primary care management of uncomplicated male hypogonadism, with referral to a specialist reserved for cases involving infertility concerns, pituitary pathology, or age under 18.

Telehealth TRT clinics. Several national telehealth platforms are licensed to prescribe in Wisconsin. These typically offer a streamlined process: upload existing labs or order new ones through a partner lab network (Quest, Labcorp, or local draws), complete a video consultation, and receive the prescription within 48 to 72 hours if clinically appropriate. The prescription is then sent to a retail or specialty pharmacy in Wisconsin.

Board-certified physicians (MD or DO), nurse practitioners, and physician assistants can all prescribe Jatenzo in Wisconsin, provided they hold appropriate state licensure and DEA registration. NPs in Wisconsin practice under a collaborative agreement, not full practice authority, per Wisconsin Statute § 441.16.

Timeline: From First Lab Draw to Capsule in Hand

The full process, from initial lab work to receiving Jatenzo, typically spans 10 to 21 days under normal conditions. Here is what that looks like broken down:

• Days 1 to 2: First morning testosterone lab draw
• Days 3 to 5: Results return; if low, schedule second confirmatory draw
• Days 5 to 7: Second lab draw completed
• Days 8 to 10: Results confirmed; telehealth or in-person visit scheduled and completed
• Days 10 to 12: Prescription written and submitted to pharmacy
• Days 12 to 14: Pharmacy fills prescription (specialty pharmacy may require 3 to 5 business days)
• Days 14 to 21: If prior authorization is needed, add 5 to 7 business days for insurer review

Patients using a telehealth platform with integrated lab ordering and pharmacy partnerships often compress this timeline to 7 to 10 business days. Those going through traditional specialist referral channels should plan for 6 to 10 weeks, factoring in appointment availability.

Transferring a Jatenzo Prescription to Wisconsin

If you already have an active Jatenzo prescription from another state, Wisconsin pharmacies can accept a transferred Schedule III prescription under federal and state transfer rules. The originating pharmacy contacts the receiving Wisconsin pharmacy directly. Both must document the transfer in their records per DEA regulations (21 CFR § 1306.25).

One limitation: Schedule III prescriptions are valid for a maximum of 6 months from the date written and allow up to 5 refills. If the prescription is near expiration or all refills have been used, a new prescription from a Wisconsin-licensed provider is necessary.

For patients relocating to Wisconsin, the most efficient approach is to establish care with a local or telehealth provider before your existing refills run out. Bring your most recent lab results, the name and dose of your current formulation, and a record of your prescribing history. Most providers will continue an established TRT regimen without repeating the full diagnostic workup, provided labs are less than 6 months old and show appropriate levels.

Monitoring After Starting Jatenzo

The FDA label and the Endocrine Society's 2018 testosterone therapy guidelines agree on a monitoring schedule that Wisconsin prescribers should follow:

• 2 to 4 weeks after initiation: Serum total testosterone drawn 4 to 6 hours post-dose for initial dose titration
• 3 months: Hematocrit, liver function tests, lipid panel, blood pressure
• 6 months: Repeat testosterone level, hematocrit, PSA (if over 40), blood pressure
• Annually thereafter: Full panel including testosterone, hematocrit, PSA, lipids, metabolic panel, blood pressure

Dr. Ronald Swerdloff, lead investigator on the Jatenzo registration trial and professor of medicine at UCLA, stated: "The oral route offers a meaningful alternative for men who cannot or prefer not to use injections, but it requires the same rigorous monitoring as any testosterone formulation, particularly for cardiovascular risk factors."

The Endocrine Society guidelines specifically recommend against initiating testosterone therapy in men with hematocrit above 50%, untreated severe obstructive sleep apnea, uncontrolled heart failure, or a recent (within 6 months) myocardial infarction or stroke. These contraindications apply regardless of the formulation or the state in which the prescription is written.

A second clinical perspective from the AUA guidelines: "Clinicians should inform patients of the absence of evidence linking testosterone therapy to the development of prostate cancer" while noting that monitoring with PSA and digital rectal exam remains standard of care for men on TRT over age 40.

Hematocrit monitoring deserves particular emphasis with Jatenzo. In the Swerdloff registration trial, 5.4% of subjects developed hematocrit values exceeding 54%, the threshold at which dose adjustment or discontinuation is recommended. This rate was lower than that typically reported with injectable testosterone (up to 20% in some studies), likely because the oral route avoids the supraphysiologic peak levels that injectable formulations produce.